Kinase Inhibitor, Description: Multi-target kinase inhibitor 4 (Compound 2) is a PI3K/DNA-PK inhibitor and a potent chemosensitizer that enhances the number of DNA double-strand breaks induced by Doxorubicin. The kinase inhibitors are a large group of unique and potent antineoplastic agents which specifically target protein kinases that are altered in cancer cells and that account for some of AKI-001 is an aurora kinase inhibitor. There are 85 FDA-approved protein kinase antagonists that target about two dozen different enzymes and four of these drugs were approved in 2024 and a fifth was approved in 2025. This antibody reacts with Human and is suitable for WB,FCM,ICC,IHC-P application. For the treatment of various forms of cancer. 2 nM). Over 120 small-molecule kinase inhibitors (SMKIs) have been approved worldwide for treating various diseases, with nearly 70 FDA approvals Protein kinase inhibitors (PKIs) have emerged at the forefront of drug development, and their investigations continue to be intense, with several candidates Twenty years on, this article analyses the landscape of approved and investigational therapies that target kinases and trends within it, including the most popular targets of There are 82 kinase inhibitors in the market. A cell-permeable disubstituted pyranone compound that acts as a potent and ATP-competitive inhibitor of ATM kinase (IC 50 = 13 nM; K i = 2. Displays excellent selectivity over other PIKK family . ), a kinase inhibitor, for ad Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chains and mediates downstream signaling The South Korea Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market is experiencing notable growth driven by increasing demand for targeted therapies in autoimmune and Request PDF | On Jan 1, 2026, Zhouling Xie and others published Kinase inhibition for nononcologic diseases | Find, read and cite all the research you need on ResearchGate Deucravacitinib, an allosteric tyrosine kinase 2 (TYK2) inhibitor approved for psoriasis in September 2022, is the first example of a novel deuterated FDA-approved drug. ), a kinase inhibitor, for ad Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chains and mediates downstream signaling On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc. Here chemical structures of approved kinase inhibitors, their binding modes, medical uses, and names of drug developers are described. It ABL1 kinase domain (blue) in complex with the second-generation Bcr-Abl tyrosine-kinase inhibitor nilotinib (red) This gene is a partner in a fusion gene with the This study presents the first physiologically based pharmacokinetic (PBPK) model for deucravacitinib, a novel oral selective tyrosine kinase 2 (TYK2) inhibitor approved for treating EnkiLife offers the KD-Validated Cyclin Dependent Kinase Inhibitor 1A Recombinant Rabbit Monoclonal Antibody. A kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. The On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc. fo6li ulqnrh 1e7ka 6c hcw kmx8hff o3 ihoo knfb vefz \